Interestingly, after just 3 weeks of oral administration, Hsieh et al. (2003) found that DGBXT “increased the population of cytotoxic T lymphocytes and NK cells,” while down-regulating T helper cells (CD4+/CD25+) in both the spleen and in tumor-draining lymph nodes. This evidence concerns the gene CD4 and neoplasm.